Marksans Pharma Limited has informed the Exchange regarding a press release dated May 15, 2025, titled "Marksans Pharma Limited s wholly owned subsidiary in UK, Relonchem Limited receives Marketing Authorization for the product Gabapentin 50 mg/ml oral solution".
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma's wholly owned UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency (UKMHRA) for Gabapentin 50 mg/ml oral solution. Gabapentin is commonly used to treat neuropathic pain and epilepsy, fitting into the company's CNS (central nervous system) therapeutic segment. This approval allows Relonchem to market the product in the UK market. The announcement was made via a press release dated May 15, 2025, and filed with both BSE and NSE.
This is a positive development as it expands Marksans Pharma's product portfolio in the UK market through its subsidiary. While the financial impact of a single product approval is limited, it strengthens the company's CNS segment and UK regulatory pipeline, potentially contributing to future revenue growth.